Mizuho Securities Believes CVS Health (CVS) Won’t Stop Here

In a report issued on January 14, Ann Hynes from Mizuho Securities maintained a Buy rating on CVS Health (CVSResearch Report), with a price target of $115.00. The company’s shares closed last Tuesday at $104.51, close to its 52-week high of $107.26.

According to TipRanks.com, Hynes is a 5-star analyst with an average return of 12.0% and a 65.5% success rate. Hynes covers the Healthcare sector, focusing on stocks such as Molina Healthcare, Quest Diagnostics, and Acadia Healthcare.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CVS Health with a $114.59 average price target, an 8.3% upside from current levels. In a report issued on January 11, Bank of America Securities also maintained a Buy rating on the stock with a $117.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $107.26 and a one-year low of $68.02. Currently, CVS Health has an average volume of 5.87M.

Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CVS in relation to earlier this year. Most recently, in November 2021, Troyen Brennan, the EVP and Chief Medical Officer of CVS sold 28,159 shares for a total of $2,534,310.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Headquartered in Rhode Island and founded in 1963, CVS Health Corp. is a healthcare company in the U.S. that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands.

Read More on CVS: